The HR-positive subjects exhibited a higher proportion of HER2-low breast carcinoma compared to the TNBC subjects, with 1,425 (39.2%) vs. 336 (34.8.%) (P <0.05). This evidence concerns the gene ERBB2 and breast carcinoma.